| Wednesday
| Thursday | Saturday
| Sunday |
| FRIDAY, DECEMBER
14, 2007 |
| 7:00-9:00 |
POSTER
DISCUSSION SESSION 2 & CONTINENTAL BREAKFAST - Ballroom
B |
|
| |
Metastasis |
201-210 |
| |
Patricia Steeg, PhD, Moderator
NCI, Bethesda, MD |
|
| |
|
|
| 7:00-9:00 |
POSTER
SESSION 2 & CONTINENTAL BREAKFAST - Exhibit Hall B
(#2001-2121) |
|
| |
|
|
| |
Prognosis and Response Predictions |
|
| |
Predictive Factors I
|
2001-2026 |
| |
Risk and Prevention |
|
| |
Diet and Nutrition
Familial Breast Cancer/Genetic Testing
|
2027-2031
2032-2051 |
| |
Treatment |
|
| |
Bone Metastases
Cost-Effectiveness
Endocrine Therapy
|
2052-2057
2058-2065
2066-2106 |
| |
Tumor Cell Biology |
|
| |
Immunology/Immunotherapy
Oncogenes/Tumor Suppressor Genes
|
2107-2114
2115-2121 |
| |
|
|
| 9:00-9:30 |
PLENARY LECTURE 3 –
Exhibit Hall D |
|
| |
|
|
| |
Energy balance, insulin, and breast cancer
Michael Pollak, MD
McGill University
Montreal, CANADA
|
|
| |
|
|
| 9:30-11:15 |
GENERAL SESSION 3 –
Exhibit Hall D |
|
| |
Suzanne A.W. Fuqua, PhD, Co-Moderator
Baylor College of Medicine
Houston, TX
and
Dennis Slamon, MD, PhD, Co-Moderator
David Gefffen School of Medicine, Los Angeles, CA |
|
| |
|
|
| 9:30 |
31. Genomic approaches to breast cancer subset identification and treatment.
Albertson D, Chin K, Devries S, Feiler H, Pinkel D, Spellman P, Waldman F, Wang N, Hennessy B, Mills G, Barcellos Hoff MH, Bissell M, Guan Y, Hu Z, Kuo W-L, McCormick F, Neve R, Stampfer M, Wooster R, Yaswen P, Das D, Fridlyand J, Correll E, Jin J, Nordmeyer B, Sudar D, Chew K, Dairkee S, Ljung BM, Hwang S, Esserman L, Arbushites M, Benz C, Koehler M, Marks JD, Zhou Y, Park J, Weber B, Gray J. University of California, San Francisco, CA; Lawrence Berkeley National Laboratory, Berkeley, CA; MD Anderson Cancer Center, Houston, TX; GlaxoSmithKline, King of Prussia, PA; California Pacific Medical Center, San Francisco, CA; Buck Institute for Age Research, Novato, CA; Genentech, South San Francisco, CA.
|
|
| |
|
|
| 9:45 |
32. Genome-wide analysis of DNA copy number alterations in conjunction with gene expression profiling identifies DNA amplification loci that predict distant recurrence in lymph node-negative (LNN) primary breast cancer patients.
Zhang Y, Klijn J, Yu J, Jiang J, Jatkoe T, Sieuwerts A, Martens J, Wang Y, Foekens J. Johnson & Johnson, San Diego, CA; Erasmus MC, Rotterdam, Netherlands. |
|
| |
|
|
| 10:00 |
33. Gene expression profiles of ER+/PR-breast cancer are associated with genomic instability and Akt/mTOR signaling, and predict poor patient outcome better than clinically assigned PR status.
Creighton CJ, Osborne CK, van de Vijver M, Foekens JA, Wang Y, Zhang Y, Klijn JGM, Horlings HM, Hilsenbeck SG, Lee AV, Schiff R. Baylor College of Medicine, Houston, TX; Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus MC-Daniel den Hoed, Rotterdam, Netherlands; Veridex LLC, a Johnson & Johnson Company, San Diego, CA.
|
|
| |
|
|
| 10:15 |
34. Expression of alphavbeta6 supersedes Her2 and triple-negative/basal classification of breast cancer and defines novel subgroups with poor survival: implications for breast cancer classification and treatment.
Jones JL, Thomas GJ, Duffy SW, Chou P, Gabe R, Ellis I, Green A, Saha A, Mulligan KT, Ryder K, Gillet C, Violette S, Weinreb P, Hart IR, Marshall JF. Bart's and the London, Queen Mary's School of Medicine and Dentistry, London, United Kingdom; Nottingham City Hospital, Nottingham, United Kingdom; Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge, MA.
|
|
| |
|
|
| 10:30 |
35. A stroma-related gene signature predicts resistance to epirubicin-containing neoadjuvant chemotherapy in breast cancer.
Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, André S, Piccart M, Campone M, Tubiana-Hulin M, MacGrogan G, Petit T, Jassem J, Rouanet P, Blot E, Bogaerts J, Bergh J, Iggo R, Delorenzi M. National Centre of Competence in Research (NCCR) Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), Epalinges, Switzerland; Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland; European Organisation for Research and Treatment of Cancer (EORTC), Breast Cancer Group, Brussels, Belgium; The Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland; The Anglo-Celtic Cooperative Oncology Group (ACCOG), Edinburgh University, Edinburgh, United Kingdom; The Swedish Breast Cancer Group (SweBCG), Karolinska Institute, Stockholm, Sweden. |
|
| |
|
|
| 10:45 |
36. The clinical significance of polysomy 17 in the HER2+ N9831 intergroup adjuvant trastuzumab trial.
Reinholz MM, Jenkins RB, Hillman D, Lingle WL, Davidson N, Martino S, Kaufman P, Kutteh L, Perez EA. Mayo Clinic College of Medicine, Rochester, MN; John Hopkins, Baltimore, MD; The Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Mayo Clinic College of Medicine, Jacksonville, FL.
|
|
| |
|
|
| 11:00 |
37. Multidrug resistance and breast cancer: a meta-analysis of MDR1 and its clinical significance.
Trock B, Leonessa F, Clarke R. Johns Hopkins, Baltimore, MD; Uniformed Services University of Health Sciences, Bethesda, MD; Georgetown University, Washington, DC. |
|
| |
|
|
| 11:15-12:00 |
WILLIAM L. MCGUIRE MEMORIAL
LECTURE – Exhibit Hall D |
|
| |
Sponsored by GlaxoSmithKline |
|
| |
Biomarking the oestrogen dependence of breast cancer
Mitchell Dowsett, PhD
Institute of Cancer Research/Royal Marsden NHS Trust
London, UNITED KINGDOM |
|
| |
|
|
| 12:00-1:00 |
LUNCH [Ticket Required] – Exhibit Hall A |
|
| |
|
|
| 12:30-1:45 |
CASE DISCUSSION 1 – Ballroom A |
|
| |
Jenny Chang, MD, Moderator
Case Discussion Panel
Clifford Hudis, MD
Seema Khan, MD
James Ingle, MD
Jay Harris, MD
Martine Piccart-Gebhart, MD, PhD
Nancy Davidson, MD
Beverly Parker, Patient Advocate |
|
| |
|
|
| 2:00-3:30 |
MINI-SYMPOSIUM 2 – Exhibit
Hall D |
|
| |
|
|
| |
WOMEN'S HEALTH INITIATIVE: HRT AND OTHER ISSUES |
|
| |
Peter Ravdin, MD, PhD, Moderator
MD Anderson Cancer Center , Houston, TX
|
|
| |
|
|
| 2:00 |
Introduction |
|
| |
|
|
| 2:00 |
The women's health initiative randomized trials of menopausal hormone therapy: Results and impact on clinical practice
|
|
| |
Rowan Chlebowski, MD, PhD
LA Biomedical Research Institute
Torrance, CA
|
|
| |
|
|
| 2:30 |
A review of HRT and breast cancer in other epidemiologic studies |
|
| |
Jack Cuzick, PhD
Wolfson Institute of Preventive Medicine
London, UNITED KINGDOM |
|
| |
|
|
| 3:00 |
Understanding changes in breast cancer incidence. Interactions between epidemiological and clinical trial evidence
|
|
| |
Peter Ravdin, MD, PhD
MD Anderson Cancer Center
Houston, TX
|
|
| |
|
|
| 3:30-5:30 |
GENERAL SESSION 4–
Exhibit Hall D |
|
| |
Judy Garber, MD, MPH, Co-Moderator
Dana Farber Cancer Institute,
Boston, MA
and
Debra Ikeda, MD, Co-Moderator
Stanford University, Stanford, CA |
|
| |
|
|
| 3:30 |
41. ATAC: 100 month median follow-up (FU) shows continued superior efficacy and no excess fracture risk for anastrozole (A) compared with tamoxifen (T) after treatment completion.
Forbes JF, Cuzick J, Buzdar A, Howell A, Baum M on behalf of the ATAC Trialists' Group. University of Newcastle, Calgary Mater Hospital, NSW, Australia; Cancer Research UK, UK; M.D. Anderson Cancer Center, USA; Christie Hospital, UK; Portland Hospital, UK. |
|
| |
|
|
| 3:45 |
42. Mid-term efficacy of a breast cancer screening program for women with a familial or genetic susceptibility: update of the Dutch MRI screening study (MRISC).
Klijn JGM, Obdeijn I-M, Kriege M, Boetes C, Oosterwijk JC, Tollenaar RAEM, Peterse H, Bergers E, Tilanus-Linthorst MMA, de Koning HJ, Rutgers EJT, Rijnsburger AJ, on behalf of the MRISC Study Group. Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands; University Medical Center Nijmegen, Nijmegen, Netherlands; Groningen University Medical Center, Groningen, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Netherlands Cancer Institute, Amsterdam, Netherlands; Free University Medical Center, Amsterdam, Netherlands.
|
|
| |
|
|
| 4:00 |
43. Detection of enhancing lesions on contrast-enhanced MRI of the breast using real-time virtual sonography: fusion of MRI and sonography data.
Nakano S, Yorozuya K, Takasugi M, Mouri Y, Fukutomi T, Arai O, Mitake T. Aichi Medical University, Aichi-gun, Aichi, Japan; Hitachi Medical Corporation, Kashiwa-city, Chiba, Japan. |
|
| |
|
|
| 4:15 |
44. MRI for diagnosing pure ductal carcinoma in-situ.
Kuhl CK, Schrading S, Wardelmann E, Braun M, Kuhn W, Schild HH. University of Bonn, Bonn, Germany. |
|
| |
|
|
| 4:30 |
45. Noninvasive monitoring of neoadjuvant chemotherapy using optical tomography with ultrasound localization: initial experience.
Tannenbaum S, Hegde P, Kane M, Xu C, Kurtzman S, Baccaro N, Iyer M, Wilson L, Deckers P, Zhu Q. University of Connecticut, Farmington, CT; University of Connecticut, Storrs, CT. |
|
| |
|
|
| 4:45 |
46. Tomosynthesis for the detection of breast cancer in a clinical setting.
Ikeda DM, Ruschin M, Timberg P, Svahn T, Zackrisson S, Andersson I. Radiology, Lund University, Malmoe University Hospital, Malmoe, Sweden; Radiology, Stanford University School of Medicine, Stanford, CA.
|
|
| |
|
|
| 5:00-7:00 |
POSTER DISCUSSION SESSION 3 & RECEPTION –
Ballroom B |
|
| |
Antibodies and Immunotherapy |
301-310 |
| |
Dennis Slamon, MD, PhD, Moderator
David Geffen School of Medicine, Los Angeles, CA |
|
| |
|
|
| 5:00-7:00 |
POSTER SESSION 3 & RECEPTION – Exhibit Hall B
(#3001-3115) |
|
| |
|
|
| |
Detection
and Diagnosis
Axillary/Sentinel Nodes
Diagnostic Pathology
Biopsy Techniques
|
3001-3027
3028-3041
3042-3044 |
| |
|
|
| |
Epidemiology and Outreach
Racial Aspects |
3045-3052 |
| |
|
|
| |
Treatment
Adjuvant Therapy
Hormone Replacement Therapy |
3053-3082
3083-3087 |
| |
|
|
| |
Tumor and Cell Biology
Apoptosis
Carcinogenesis
Tumor Biology
Prognosis and Response Predictions: Prognostic Factors I
Late Acceptances |
3088-3089
3090-3091
3092-3112
3113
3114-3115 |
| |
|
|
| 7:00-8:00 |
LATE-BREAKING SESSION– Exhibit Hall D |
|
| |
C. Kent Osborne , MD, Co-Moderator
Baylor College of Medicine, Houston, TX
and
Gary Chamness, PhD, Co-Moderator
Baylor College of Medicine, Houston, TX |
|
| |
|
|
| 7:00 |
47. A phase 3 study of the effect of denosumab therapy on bone mineral density in women receiving aromatase inhibitors for non-metastatic breast cancer.
Ellis G, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S. Seattle Cancer Care Alliance, Seattle, WA; Michigan Bone & Mineral Clinic, Detroit, MI; UCLA Medical Center, Torrance, CA; US Oncology, Houston, TX and Rocky Mountain Cancer Centers, Denver, CO; Algoma Regional Cancer Program, Sault Ste. Marie, ON, Canada; Amgen Inc., Thousand Oaks, CA. |
|
| |
|
|
| 7:15 |
48. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): International randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women – preliminary results.
Peto R, Davies C, on behalf of the ATLAS Collaboration. |
|
| |
|
|
| 7:30 |
49. Conditional expression of stress proteins in DCIS predicts future tumor formation.
Gauthier ML, Berman HK, Miller C, Kozakeiwicz K, Chew K, Moore D, Rabban J, Chen YY, Kerlikowske K, Tlsty TD. Department of Pathology, Comprehensive Cancer Center; California Pacific Medical Center; Departments of Epidemiology and Biostatistics; General Internal Medicine Section, Department of Veterans Affairs, University of California San Francisco, San Francisco, CA; Ontario Cancer Institute/Campbell Family Institute for Breast Cancer Research; Department of Pathology, University of Toronto, Toronto, ON, Canada.
|
|
| |
|
|
| 7:45 |
50. Breast cancer patients with 1-3 positive lymph nodes and a low risk 70-gene profile have an excellent survival.
Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Piccart MJ, Cardoso F, Rutgers EJ and Van ’t Veer LJ, on behalf of the TRANSBIG consortium. The Netherlands Cancer Institute, Amsterdam, The Netherlands; European Institute of Oncology and University of Milan, Milan, Italy
|
|
| |
|
|
|
Home
Registration
Schedule at a Glance
